<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939287</url>
  </required_header>
  <id_info>
    <org_study_id>14102001</org_study_id>
    <nct_id>NCT02939287</nct_id>
  </id_info>
  <brief_title>Aprepitant Versus Olanzapine With High Dose Melphalan</brief_title>
  <official_title>Aprepitant Versus Olanzapine for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help answer the following research question:

        -  Whether administration of an aprepitant containing regimen or an olanzapine containing
           regimen will prevent nausea and vomiting better for patients undergoing an autologous
           stem cell transplant with melphalan chemotherapy. Both of these medications are approved
           by the United States Food and Drug Administration (FDA) for nausea and vomiting.

        -  Participants will be randomly assigned to one of the 2 treatment groups:

             -  Arm A: aprepitant plus standard anti-emetic regimen

             -  Arm B: olanzapine plus standard anti-emetic regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, non-inferiority phase 3 study conducted to determine an
      appropriate anti-emetic regimen for patients receiving melphalan for an autologous stem cell
      transplant (SCT). Candidates for this trial will include patients aged 18-80 years with
      hematologic malignancies receiving high dose melphalan as part of a conditioning regimen for
      an autologous stem cell transplant. Patients will be enrolled in 2 arms. Patients in Arm A
      will receive an aprepitant containing anti-emetic regimen. Patients in Arm B will receive an
      olanzapine containing anti-emetic regimen. Patients must be able to tolerate oral
      medications.

      Patients will be carefully monitored for rates of emesis, nausea, and mucositis. Any adverse
      events will be recorded. Impact on quality of life will also be assessed. A total of 184
      patients will be accrued to each arm. It is anticipated that the accrual period will last
      approximately 2-3 years. The primary endpoint of this study is a complete response, defined
      as no emesis and no rescue therapy within 120 hours of melphalan administration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR)</measure>
    <time_frame>within 120 hours following melphalan administration</time_frame>
    <description>no emesis and no rescue anti-emetic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute complete response</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>no emesis or rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed complete response</measure>
    <time_frame>25-120 hours</time_frame>
    <description>no emesis or rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very delayed complete response</measure>
    <time_frame>121-168 hours</time_frame>
    <description>no emesis or rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucositis/Significant mucositis</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aprepitant plus standard anti-emetic regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine plus standard anti-emetic regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Add aprepitant to anti-emetic regimen</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>add olanzapine to anti-emetic regimen</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autologous transplant containing high dose melphalan as part of the conditioning
             regimen (single or 2 day melphalan; BEAM [carmustine, etoposide, cytarabine,
             melphalan])

          -  able to tolerate oral medications

        Exclusion Criteria:

          -  Nausea/vomiting within 12 hours before planned high dose conditioning chemotherapy

          -  Any anti-emetic treatment within 24 hours before planned high dose conditioning
             chemotherapy

          -  Pregnancy

          -  Baseline corrected QT interval (QTc) &gt; 500 ms

          -  History of seizures

          -  History of central nervous system (CNS) disease

          -  Human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Schultz, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Schultz, PharmD</last_name>
    <phone>3129472405</phone>
    <email>kathryn_schultz@rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunita Nathan, MD</last_name>
    <phone>312-942-1424</phone>
    <email>sunita_nathan@rush.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011 Nov 1;29(31):4189-98. doi: 10.1200/JCO.2010.34.4614. Epub 2011 Sep 26. Review. Erratum in: J Clin Oncol. 2014 Jun 1;32(19):2117. Dosage error in article text.</citation>
    <PMID>21947834</PMID>
  </reference>
  <reference>
    <citation>Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct;9(5):188-95. doi: 10.1016/j.suponc.2011.05.002. Epub 2011 Sep 24.</citation>
    <PMID>22024310</PMID>
  </reference>
  <reference>
    <citation>Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011 Apr;22(4):939-46. doi: 10.1093/annonc/mdq457. Epub 2010 Oct 8.</citation>
    <PMID>20935058</PMID>
  </reference>
  <reference>
    <citation>Slabý J, Trnený M, Procházka B, Klener P. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma. 2000;47(5):319-22.</citation>
    <PMID>11130251</PMID>
  </reference>
  <reference>
    <citation>Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant. 2001 Dec;28(11):1061-6.</citation>
    <PMID>11781617</PMID>
  </reference>
  <reference>
    <citation>Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4. doi: 10.1007/s00520-010-0920-z. Epub 2010 May 26.</citation>
    <PMID>20505956</PMID>
  </reference>
  <reference>
    <citation>Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011 Jun;46(6):784-9. doi: 10.1038/bmt.2010.205. Epub 2010 Sep 13.</citation>
    <PMID>20838387</PMID>
  </reference>
  <reference>
    <citation>Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc. 2011 Oct;43(8):3107-10. doi: 10.1016/j.transproceed.2011.08.010.</citation>
    <PMID>21996238</PMID>
  </reference>
  <reference>
    <citation>Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, Porter N, Go A, Smith SE, Rodriguez TE. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013 Jan;19(1):49-55.e1. doi: 10.1016/j.bbmt.2012.07.019. Epub 2012 Aug 1.</citation>
    <PMID>22863840</PMID>
  </reference>
  <reference>
    <citation>Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. J Pain Symptom Manage. 2002 Apr;23(4):346-50.</citation>
    <PMID>11997204</PMID>
  </reference>
  <reference>
    <citation>Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001 Nov 2;430(2-3):341-9.</citation>
    <PMID>11711053</PMID>
  </reference>
  <reference>
    <citation>Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006 Sep 20;24(27):4472-8.</citation>
    <PMID>16983116</PMID>
  </reference>
  <reference>
    <citation>Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl le H, Mikus G, Burhenne J, Ho AD, Egerer G. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol. 2014 Oct 20;32(30):3413-20. doi: 10.1200/JCO.2013.55.0095. Epub 2014 Sep 15.</citation>
    <PMID>25225424</PMID>
  </reference>
  <reference>
    <citation>Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003 Aug;11(8):522-7. Epub 2003 Jun 25.</citation>
    <PMID>12827483</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous</keyword>
  <keyword>myeloma</keyword>
  <keyword>transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

